Abstract
Combination therapy involves the simultaneous administration of compounds with varying mechanisms of action that can improve the efficacy of antitumor therapy and reduce toxicity. The most widely used combination regimen is chemotherapy combined with focused immunotherapy. This is implemented to induce the apoptosis of tumor cells and can activate immune responses, improving the clearance rate of primary lesions and maintaining the resistance to postoperative tumor recurrence and metastasis. Advances in micro/nanotechnology, nanomedicine and biomaterials have contributed to the development of enhanced local drug co-delivery systems for cancer treatment, improving tumor targeting and ameliorating severe systemic complications. Carrier materials can achieve the local long-term controllable release of multiple drugs, which not only avoids rapid drug diffusion from the pathological site, but can achieve synergistic effects at lower drug concentrations. Polymeric carriers display excellent biocompatibility and biodegradability; especially, some of them also have anti-tumor effects. The aim of this article was to review recent progress in the use of organic and polymeric materials for local tumor chemo-immunotherapy, which can be used as carriers for chemotherapeutic drugs, immune adjuvants and genes, including amphiphilic nanoparticles, nanocapsules, nano-disks, nano-polyplex particles, hydrogels and implantable materials.
Similar content being viewed by others
References
Pardoll D M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12: 252–264
Park S B, Goldstein D, Krishnan A V, et al. Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA Cancer J Clin, 2013, 63: 419–437
Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol, 2012, 23: vii155–vii166
Lee S M, O’Halloran T V, Nguyen S B T. Polymer-caged nanobins for synergistic cisplatin-doxorubicin combination chemotherapy. J Am Chem Soc, 2010, 132: 17130–17138
Zheng M, Yue C, Ma Y, et al. Single-step assembly of DOX/ICG loaded lipid-polymer nanoparticles for highly effective chemo-photothermal combination therapy. ACS Nano, 2013, 7: 2056–2067
Chen Z, Cheng K, Walton Z, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature, 2012, 483: 613–617
Park S J, Cheong H I, Shin J I. Antibody depletion by bortezomib through blocking of antigen presentation. New Engl J Med, 2013, 368: 1364–1365
Lake R A, Robinson B W S. Immunotherapy and chemotherapy—A practical partnership. Nat Rev Cancer, 2005, 5: 397–405
Nowak A K, Robinson B W S, Lake R A. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res, 2003, 63: 4490–4496
Stewart J M, Keselowsky B G. Combinatorial drug delivery approaches for immunomodulation. Adv Drug Deliver Rev, 2017, 114: 161–174
Whiteside T L. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol, 2006, 16: 3–15
Zamarron B F, Chen W J. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci, 2011, 7: 651–658
Holohan C, Van Schaeybroeck S, Longley D B, et al. Cancer drug resistance: An evolving paradigm. Nat Rev Cancer, 2013, 13: 714–726
Rebucci M, Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol, 2013, 85: 1219–1226
Makadia H K, Siegel S J. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers, 2011, 3: 1377–1397
LaVan D A, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol, 2003, 21: 1184–1191
Doshi N, Mitragotri S. Designer biomaterials for nanomedicine. Adv Funct Mater, 2009, 19: 3843–3854
Ma H, He C, Chen X. Injectable hydrogels as local depots at tumor sites for antitumor immunotherapy and immune-based combination therapy. Macromol Biosci, 2021, 21: e2100039
Kim J, Manspeaker M P, Thomas S N. Augmenting the synergies of chemotherapy and immunotherapy through drug delivery. Acta Biomater, 2019, 88: 1–14
He Z, Huang J, Xu Y, et al. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer. Oncotarget, 2015, 6: 42150–42168
Nascimento A V, Singh A, Bousbaa H, et al. Combinatorial-designed epidermal growth factor receptor-targeted chitosan nanoparticles for encapsulation and delivery of lipid-modified platinum derivatives in wild-type and resistant non-small-cell lung cancer cells. Mol Pharm, 2015, 12: 4466–4477
Guo S, Wang Y, Miao L, et al. Turning a water and oil insoluble cisplatin derivative into a nanoparticle formulation for cancer therapy. Biomaterials, 2014, 35: 7647–7653
Aliabadi H M, Lavasanifar A. Polymeric micelles for drug delivery. Expert Opin Drug Deliver, 2006, 3: 139–162
He C, Zhuang X, Tang Z, et al. Stimuli-sensitive synthetic poly-peptide-based materials for drug and gene delivery. Adv Healthcare Mater, 2012, 1: 48–78
Chen J, Huang K, Chen Q, et al. Tailor-making fluorescent hyaluronic acid microgels via combining microfluidics and photoclick chemistry for sustained and localized delivery of herceptin in tumors. ACS Appl Mater Interf, 2018, 10: 3929–3937
Xie X, Hu Y, Ye T, et al. Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen. Nat Biomed Eng, 2021, 5: 414–428
Zhang Z, Zhang Q, Xie J, et al. Enzyme-responsive micellar JQ1 induces enhanced BET protein inhibition and immunotherapy of malignant tumors. Biomater Sci, 2021, 9: 6915–6926
Nitiss J L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer, 2009, 9: 338–350
Cravens P D, Lipsky P E. Dendritic cells, chemokine receptors and autoimmune inflammatory diseases. Immunol Cell Biol, 2002, 80: 497–505
Da Silva C G, Camps M G M, Li T M W Y, et al. Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles. Theranostics, 2019, 9: 6485–6500
Kuai R, Yuan W, Son S, et al. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. Sci Adv, 2018, 4: eaao1736
Liao F, Rabin R L, Smith C S, et al. CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inflammatory protein 3 alpha. J Immunol, 1999, 162: 186–194
Pasare C, Medzhitov R. Toll-like receptors: Linking innate and adaptive immunity. Microbes Infect, 2004, 6: 1382–1387
Heo M B, Kim S Y, Yun W S, et al. Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy. Int J Nanomed, 2015, 10: 5981–5992
Danhier F, Messaoudi K, Lemaire L, et al. Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: In vivo evaluation. Int J Pharm, 2015, 481: 154–161
Kadiyala P, Li D, Nunez F M, et al. High-density lipoprotein-mi-micking nanodiscs for chemo-immunotherapy against glioblastoma multiforme. ACS Nano, 2019, 13: 1365–1384
Sonabend A M, Velicu S, Ulasov I V, et al. A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma. Anti-Cancer Drugs, 2008, 19: 133–142
Hood R L, Bruno G, Jain P, et al. Nanochannel implants for minimally-invasive insertion and intratumoral delivery. J Biomed Nanotechnol, 2016, 12: 1907–1915
Phuengkham H, Song C, Um S H, et al. Implantable synthetic immune niche for spatiotemporal modulation of tumor-derived immunosuppression and systemic antitumor immunity: Postoperative immunotherapy. Adv Mater, 2018, 30: e1706719
Ren L, Lim Y T. Degradation-regulatable architectured implantable macroporous scaffold for the spatiotemporal modulation of immunosuppressive microenvironment and enhanced combination cancer immunotherapy. Adv Funct Mater, 2018, 28: 1804490
Seo S H, Han H D, Noh K H, et al. Chitosan hydrogel containing GMCSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8+ T cell-mediated anti-tumor immunity. Clin Exp Metastasis, 2009, 26: 179–187
Sun L, Shen F, Tian L, et al. ATP-responsive smart hydrogel releasing immune adjuvant synchronized with repeated chemotherapy or radiotherapy to boost antitumor immunity. Adv Mater, 2021, 33: e2007910
Nishikawa M, Mizuno Y, Mohri K, et al. Biodegradable CpG DNA hydrogels for sustained delivery of doxorubicin and immunostimulatory signals in tumor-bearing mice. Biomaterials, 2011, 32: 488–494
Chen M, Tan Y, Dong Z, et al. Injectable anti-inflammatory nanofiber hydrogel to achieve systemic immunotherapy post local administration. Nano Lett, 2020, 20: 6763–6773
Wu X, He C, Wu Y, et al. Nanogel-incorporated physical and chemical hybrid gels for highly effective chemo-protein combination therapy. Adv Funct Mater, 2015, 25: 6744–6755
Li Y, Fang M, Zhang J, et al. Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. OncoImmunology, 2016, 5: e1074374
Chao Y, Liang C, Tao H, et al. Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses. Sci Adv, 2020, 6: eaaz4204
Wang H, Najibi A J, Sobral M C, et al. Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors. Nat Commun, 2020, 11: 5696
Wu X, Wu Y, Ye H, et al. Interleukin-15 and cisplatin co-encapsulated thermosensitive polypeptide hydrogels for combined immuno-chemotherapy. J Control Release, 2017, 255: 81–93
Shi Y, Li D, He C, et al. Design of an injectable polypeptide hydrogel depot containing the immune checkpoint blocker anti-PD-L1 and doxorubicin to enhance antitumor combination therapy. Macromol Biosci, 2021, 21: e2100049
Jiang L, Ding Y, Xue X, et al. Entrapping multifunctional dendritic nanoparticles into a hydrogel for local therapeutic delivery and synergetic immunochemotherapy. Nano Res, 2018, 11: 6062–6073
Wang C, Wang J, Zhang X, et al. In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. Sci Transl Med, 2018, 10: eaan3682
Gong Y, Chen M, Tan Y, et al. Injectable reactive oxygen species-responsive SN38 prodrug scaffold with checkpoint inhibitors for combined chemoimmunotherapy. ACS Appl Mater Interfaces, 2020, 12: 50248–50259
Wang F, Xu D, Su H, et al. Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker-based immunotherapy. Sci Adv, 2020, 6: eaaz8985
Wang F, Su H, Xu D, et al. Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel. Nat Biomed Eng, 2020, 4: 1090–1101
Jin H, Wan C, Zou Z, et al. Tumor ablation and therapeutic immunity induction by an injectable peptide hydrogel. ACS Nano, 2018, 12: 3295–3310
Phillips M A, Gran M L, Peppas N A. Targeted nanodelivery of drugs and diagnostics. Nano Today, 2010, 5: 143–159
Astete C E, Sabliov C M. Synthesis and characterization of PLGA nanoparticles. J BioMater Sci Polym Ed, 2006, 17: 247–289
Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol, 2001, 31: 3026–3037
Bode C, Zhao G, Steinhagen F, et al. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines, 2011, 10: 499–511
Pradhan P, Qin H, Leleux J A, et al. The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. Biomaterials, 2014, 35: 5491–5504
Roy A, Singh M S, Upadhyay P, et al. Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model. Int J Pharm, 2013, 445: 171–180
Lee I H, An S, Yu M K, et al. Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates. J Control Release, 2011, 155: 435–441
Yin Y, Hu Q, Xu C, et al. Co-delivery of doxorubicin and interferon-γ by thermosensitive nanoparticles for cancer immunochemotherapy. Mol Pharm, 2018, 15: 4161–4172
Sharp F A, Ruane D, Claass B, et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci USA, 2009, 106: 870–875
Wolfram J, Zhu M, Yang Y, et al. Safety of nanoparticles in medicine. Current Drug Targets, 2015, 16: 1671–1681
Huynh N T, Passirani C, Saulnier P, et al. Lipid nanocapsules: A new platform for nanomedicine. Int J Pharm, 2009, 379: 201–209
Battaglia L, Gallarate M. Lipid nanoparticles: State of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliver, 2012, 9: 497–508
Bernardi A, Braganhol E, Jäger E, et al. Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett, 2009, 281: 53–63
Friedman H S, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res, 2000, 6: 2585–2597
Messaoudi K, Saulnier P, Boesen K, et al. Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide. Int J Nanomedicine, 2014, 9: 1479–1490
Malmo J, Sørgård H, Vårum K M, et al. siRNA delivery with chitosan nanoparticles: Molecular properties favoring efficient gene silencing. J Control Release, 2012, 158: 261–268
Han L, Zhao J, Zhang X, et al. Enhanced siRNA delivery and silencing gold-chitosan nanosystem with surface charge-reversal polymer assembly and good biocompatibility. ACS Nano, 2012, 6: 7340–7351
Kim D H, Rossi J J. Strategies for silencing human disease using RNA interference. Nat Rev Genet, 2007, 8: 173–184
Allard E, Passirani C, Benoit J P. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials, 2009, 30: 2302–2318
Bayburt T H, Sligar S G. Membrane protein assembly into Nanodiscs. FEBS Lett, 2010, 584: 1721–1727
Denisov I G, Sligar S G. Nanodiscs in membrane biochemistry and biophysics. Chem Rev, 2017, 117: 4669–4713
van Tellingen O, Yetkin-Arik B, de Gooijer M C, et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resistance Updates, 2015, 19: 1–12
Vickers K C, Palmisano B T, Shoucri B M, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol, 2011, 13: 423–433
Kuai R, Li D, Chen Y E, et al. High-density lipoproteins: Nature’s multifunctional nanoparticles. ACS Nano, 2016, 10: 3015–3041
Yuan Y, Wen J, Tang J, et al. Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin. Int J Nanomed, 2016, 11: 6229–6238
Krause B R, Remaley A T. Reconstituted HDL for the acute treatment of acute coronary syndrome. Curr Opin Lipidol, 2013, 24: 480–486
Zhao D, Alizadeh D, Zhang L, et al. Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity. Clin Cancer Res, 2011, 17: 771–782
Fan H, Zhang I, Chen X, et al. Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice. Clin Cancer Res, 2012, 18: 5628–5638
Lollo G, Vincent M, Ullio-Gamboa G, et al. Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma. Int J Pharm, 2015, 495: 972–980
Alifieris C, Trafalis D T. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol Ther, 2015, 152: 63–82
Mahato R I, Lee M, Han S, et al. Intratumoral delivery of p2CMVmIL-12 using water-soluble lipopolymers. Mol Ther, 2001, 4: 130–138
Wang D, Narang A S, Kotb M, et al. Novel branched poly(ethylenimine)-cholesterol water-soluble lipopolymers for gene delivery. Biomacromolecules, 2002, 3: 1197–1207
Fewell J G, Matar M, Slobodkin G, et al. Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer. J Control Release, 2005, 109: 288–298
Tan J, Newton C A, Djeu J Y, et al. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res, 1996, 56: 3399–3403
Voest E E, Kenyon B M, O’Reilly M S, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst, 1995, 87: 581–586
Sgadari C, Angiolillo A L, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood, 1996, 87: 3877–3882
Wei J, Barr J, Kong L Y, et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther, 2010, 9: 67–78
Duvic M, Sherman M L, Wood G S, et al. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol, 2006, 55: 807–813
Gollob J A, Mier J W, Veenstra K, et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res, 2000, 6: 1678–1692
Fine D, Grattoni A, Hosali S, et al. A robust nanofluidic membrane with tunable zero-order release for implantable dose specific drug delivery. Lab Chip, 2010, 10: 3074–3083
Park S N, Lee H J, Lee K H, et al. Biological characterization of EDC-crosslinked collagen-hyaluronic acid matrix in dermal tissue restoration. Biomaterials, 2003, 24: 1631–1641
Burdick J A, Prestwich G D. Hyaluronic acid hydrogels for biomedical applications. Adv Mater, 2011, 23: H41–H56
Phuengkham H, Song C, Lim Y T. A designer scaffold with immune nanoconverters for reverting immunosuppression and enhancing immune checkpoint blockade therapy. Adv Mater, 2019, 31: e1903242
Jurk M, Heil F, Vollmer J, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol, 2002, 3: 499
Rodell C B, Arlauckas S P, Cuccarese M F, et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat Biomed Eng, 2018, 2: 578–588
Vasilakos J P, Tomai M A. The use of toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Rev Vaccines, 2013, 12: 809–819
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J ImmunoTher Cancer, 2018, 6: 56
Si X, Ji G, Ma S, et al. Biodegradable implants combined with immunogenic chemotherapy and immune checkpoint therapy for peritoneal metastatic carcinoma postoperative treatment. ACS Biomater Sci Eng, 2020, 6: 5281–5289
Ji G, Zhang Y, Si X, et al. Biopolymer immune implants’ sequential activation of innate and adaptive immunity for colorectal cancer postoperative immunotherapy. Adv Mater, 2021, 33: e2004559
Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliver Rev, 2001, 53: 321–339
He C, Kim S W, Lee D S. In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. J Control Release, 2008, 127: 189–207
Yu L, Ding J. Injectable hydrogels as unique biomedical materials. Chem Soc Rev, 2008, 37: 1473–1481
Hoffman A S. Hydrogels for biomedical applications. Adv Drug Deliver Rev, 2012, 64: 18–23
Li Q Y, Xu Z Y, Zhang D F, et al. T-shaped trifunctional crosslinker-toughening hydrogels. Sci China Tech Sci, 2020, 63: 1721–1729
Rong Y, Zhang Z, He C L, et al. Matrix metalloproteinase-sensitive poly(ethylene glycol)/peptide hydrogels as an interactive platform conducive to cell proliferation during 3D cell culture. Sci China Tech Sci, 2021, 64: 1285–1294
Shi S, Wang J Y, Wang T R, et al. Influence of residual chirality on the conformation and enzymatic degradation of glycopolypeptide based biomaterials. Sci China Tech Sci, 2021, 64: 641–650
Zou Y, Jin X, Zhang X P, et al. A multifunctional biomedical patch based on hyperbranched epoxy polymer and MXene. Sci China Tech Sci, 2021, 64: 2744–2754
Singh A, Peppas N A. Hydrogels and scaffolds for immunomodulation. Adv Mater, 2014, 26: 6530–6541
Wu X, He C, Wu Y, et al. Synergistic therapeutic effects of Schiff’s base cross-linked injectable hydrogels for local co-delivery of metformin and 5-fluorouracil in a mouse colon carcinoma model. Biomaterials, 2016, 75: 148–162
Molinaro G, Leroux J C, Damas J, et al. Biocompatibility of thermosensitive chitosan-based hydrogels: An in vivo experimental approach to injectable biomaterials. Biomaterials, 2002, 23: 2717–2722
Ruel-Gariépy E, Shive M, Bichara A, et al. A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel. Europ J Pharma Biopharma, 2004, 57: 53–63
Nowak A K, Lake R A, Robinson B W. Combined chemoimmunotherapy of solid tumours: Improving vaccines? Adv Drug Deliv Rev, 2006, 58: 975–990
Serafini P, Carbley R, Noonan K A, et al. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res, 2004, 64: 6337–6343
Albert M L, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature, 1998, 392: 86–89
Judson I R. Anthrapyrazoles: True successors to the anthracyclines? Anti-Cancer Drugs, 1991, 2: 223–231
Gačanin J, Synatschke C V, Weil T. Biomedical applications of DNA-based hydrogels. Adv Funct Mater, 2019, 30: 1906253
Bauer S, Kirschning C J, Häcker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA, 2001, 98: 9237–9242
Vollmer J, Krieg A M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliver Rev, 2009, 61: 195–204
Koyama S, Akbay E A, Li Y Y, et al. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res, 2016, 76: 999–1008
Oh J K, Drumright R, Siegwart D J, et al. The development of microgels/nanogels for drug delivery applications. Prog Polym Sci, 2008, 33: 448–477
Leonard W J, O’Shea J J. JAKS AND STATS: Biological implications. Annu Rev Immunol, 1998, 16: 293–322
Zhu M, John S, Berg M, et al. Functional association of NMI with Stat5 and Stat1 in IL-2- and IFN γ-mediated signaling. Cell, 1999, 96: 121–130
Negoro S, Oh H, Tone E, et al. Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation, 2001, 103: 555–561
Rossé T, Olivier R, Monney L, et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature, 1998, 391: 496–499
Lee K Y, Mooney D J. Alginate: Properties and biomedical applications. Prog Polym Sci, 2012, 37: 106–126
Ruvinov E, Cohen S. Alginate biomaterial for the treatment of myocardial infarction: Progress, translational strategies, and clinical outlook. Adv Drug Deliver Rev, 2016, 96: 54–76
Selmi T A S, Verdonk P, Chambat P, et al. Autologous chondrocyte implantation in a novel alginate-agarose hydrogel. J Bone Joint Surg Br volume, 2008, 90-B: 597–604
Keir M E, Butte M J, Freeman G J, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol, 2008, 26: 677–704
Zou W, Wolchok J D, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med, 2016, 8: 328rv4
Alsaab H O, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front Pharmacol, 2017, 8: 561
Dannenberg A J, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia. Cancer Cell, 2003, 4: 431–436
Obermajer N, Muthuswamy R, Odunsi K, et al. PGE2-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res, 2011, 71: 7463–7470
Leahy K M, Ornberg R L, Wang Y, et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res, 2002, 62: 625–631
Michot J M, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur J Cancer, 2016, 54: 139–148
Galluzzi L, Buqué A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell, 2015, 28: 690–714
Emens L A, Middleton G. The interplay of immunotherapy and chemotherapy: Harnessing potential synergies. Cancer Immunol Res, 2015, 3: 436–443
Martins I, Wang Y, Michaud M, et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ, 2014, 21: 79–91
Dimitrov I, Trzebicka B, Müller A H E, et al. Thermosensitive water-soluble copolymers with doubly responsive reversibly interacting entities. Prog Polym Sci, 2007, 32: 1275–1343
Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliver Rev, 2012, 64: 49–60
Steel J C, Waldmann T A, Morris J C. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci, 2012, 33: 35–41
Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer, 2007, 7: 573–584
Lv Q, He C, Quan F, et al. DOX/IL-2/IFN-γ co-loaded thermosensitive polypeptide hydrogel for efficient melanoma treatment. Bioactive Mater, 2018, 3: 118–128
Lechner M, Lirk P, Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: The two sides of the same coin. Semin Cancer Biol, 2005, 15: 277–289
Fukumura D, Kashiwagi S, Jain R K. The role of nitric oxide in tumour progression. Nat Rev Cancer, 2006, 6: 521–534
Sena L A, Chandel N S. Physiological roles of mitochondrial reactive oxygen species. Mol Cell, 2012, 48: 158–167
Chen X, Song M, Zhang B, et al. Reactive oxygen species regulate T cell immune response in the tumor microenvironment. Oxid Med Cell Longev, 2016, 2016: 1580967
Nathan C, Cunningham-Bussel A. Beyond oxidative stress: an immunologist’s guide to reactive oxygen species. Nat Rev Immunol, 2013, 13: 349–361
Toschi L, Finocchiaro G, Bartolini S, et al. Role of gemcitabine in cancer therapy. Future Oncology (London, England), 2005, 1: 7–17
Zhang P, Su D M, Liang M, et al. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol, 2008, 45: 1470–1476
Ginn-Pease M E, Whisler R L. Redox signals and NF-κB activation in T cells. Free Radical Biol Med, 1998, 25: 346–361
Zhang Y, Choksi S, Chen K, et al. ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages. Cell Res, 2013, 23: 898–914
Nishikawa M. Reactive oxygen species in tumor metastasis. Cancer Lett, 2008, 266: 53–59
Sharma A, Lee M G, Won M, et al. Targeting heterogeneous tumors using a multifunctional molecular prodrug. J Am Chem Soc, 2019, 141: 15611–15618
Corrales L, Glickman L H, McWhirter S M, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep, 2015, 11: 1018–1030
Raghuraman H, Chattopadhyay A. Melittin: A membrane-active peptide with diverse functions. Biosci Rep, 2007, 27: 189–223
Trédan O, Galmarini C M, Patel K, et al. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst, 2007, 99: 1441–1454
Jain R K. Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers. J Clin Oncol, 2013, 31: 2205–2218
Author information
Authors and Affiliations
Corresponding authors
Additional information
This work was supported by the National Natural Science Foundation of China (Grant Nos. 51973218, 51833010, 51622307), and the Youth Innovation Promotion Association of the Chinese Academy of Sciences.
Rights and permissions
About this article
Cite this article
Bai, Y., Wang, T., Zhang, S. et al. Recent advances in organic and polymeric carriers for local tumor chemo-immunotherapy. Sci. China Technol. Sci. 65, 1011–1028 (2022). https://doi.org/10.1007/s11431-021-1961-y
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1007/s11431-021-1961-y